01—Abstract
Summary
Summary of the 10-K/A filed February 28, 2013. Cited figures are marked; the original filing is the authoritative source.
Thermo Fisher Scientific Inc. (TMO) filed its 2012 10-K on February 27, 2013, detailing its financial performance and strategic positioning.
The company continued to demonstrate strong execution, driven by its diverse portfolio of products and services that serve a broad range of customers in life sciences research, healthcare, industrial, and applied markets. Key to its success was the ongoing integration of its acquired businesses and a focus on innovation to maintain its competitive edge. Investors should note the company's commitment to expanding its global reach and investing in high-growth areas within the life sciences sector.
02—Key points
Key Highlights
- Thermo Fisher Scientific operates in a dynamic and growing life sciences and diagnostics market.
- The company's diversified business model across various end markets (life sciences research, healthcare, industrial, applied) provides resilience.
- Strategic acquisitions and integrations are a key part of the company's growth strategy.
- Focus on innovation and product development to drive organic growth.
- Commitment to expanding global presence and serving a broad customer base.
- The company is well-positioned to benefit from trends in personalized medicine and biopharmaceutical manufacturing.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2012, Thermo Fisher Scientific kept $0.09.
- Revenue$12.51B100.0%
- Cost of revenue−$6.10B48.8%
- Gross profit$6.41B51.2%
- Operating costs−$4.93B39.4%
- Operating income$1.48B11.8%
- Interest, other & tax−$304.2M2.4%
- Net income$1.18B9.4%
Where FY2012 revenue went
$12.51B- Cost of revenue: $6.10B, 49% of revenue
- SG&A: $3.35B, 27% of revenue
- Net income: $1.18B, 9.4% of revenue
- R&D: $376.4M, 3.0% of revenue
- Other operating costs: $1.20B, 9.6% of revenue
- Interest, other & tax: $304.2M, 2.4% of revenue
Kept 9.4% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-K/AFY2012filed February 28, 2013Financial Statements
FY2012 against FY2011
| Line item | FY2012FY2011 | Change |
|---|---|---|
| Revenue | $12.51B$11.56B | +8.2% |
| Cost of Revenue | $6.10B$5.73B | +6.4% |
| Gross Profit | $6.41B$5.83B | +10.0% |
| R&D Expenses | $376.40M$340.20M | +10.6% |
| SG&A Expenses | $3.35B$3.11B | +8.0% |
| Operating Expenses | $11.03B$10.31B | +7.0% |
| Operating Income | $1.48B$1.25B | +18.5% |
| Interest Expense | $241.60M$175.30M | +37.8% |
| Net Income | $1.18B$1.33B | −11.4% |
| EPS (Basic) | $3.24$3.49 | −7.2% |
| EPS (Diluted) | $3.21$3.46 | −7.2% |
| Shares Outstanding (Basic) | 363.80M380.80M | −4.5% |
| Shares Outstanding (Diluted) | 366.60M384.80M | −4.7% |
05—Questions
Frequently Asked Questions
What are Thermo Fisher Scientific's primary revenue drivers?
Thermo Fisher Scientific generates revenue from a wide array of products and services, including analytical instruments, laboratory equipment, reagents, consumables, software, and services for scientific research, diagnostics, and industrial applications. Key segments often include Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
How is Thermo Fisher Scientific managing its growth and market position?
The company employs a multi-pronged strategy for growth, encompassing organic growth through innovation and new product development, as well as inorganic growth through strategic acquisitions. It focuses on integrating acquired businesses effectively to realize synergies and expand its market reach.
What are the key trends impacting Thermo Fisher Scientific's business?
Key trends include the increasing demand for biopharmaceuticals and biologics manufacturing, advancements in genetic sequencing and gene editing, the growth of personalized medicine, and the need for advanced diagnostic tools. The company's investments are often aligned with these significant market shifts.
What is the significance of the company's filings with the SEC?
SEC filings, such as the 10-K annual report, provide crucial audited financial information, management discussions, risk factors, and disclosures about the company's operations, strategy, and governance. They are essential for investors to make informed decisions about the company's performance and prospects.
06—Continue